Quantcast

Latest Sirolimus Stories

2010-09-21 20:27:19

Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer.

2010-09-21 11:54:58

A new drug-eluting stent design demonstrated superiority over a traditional drug-eluting stent at 6 months.

2010-09-21 11:52:11

Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting.

2010-09-02 06:59:00

STOCKHOLM, September 2, 2010 /PRNewswire/ -- - Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT...

2010-08-31 05:20:00

STOCKHOLM, August 31, 2010 /PRNewswire/ -- - The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a...

2010-07-01 00:25:00

EAST HANOVER, N.J., July 1 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

2010-06-05 16:39:00

EAST HANOVER, N.J., June 5 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS) (1,2).


Word of the Day
donative
  • A gift; a largess; a gratuity; a present; a dole.
The word 'donative' comes from a Latin word meaning 'to give'.
Related